Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Option Exercise and Sale

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares on April 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On April 1, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 1,667 shares of common stock at a price of $21.41 per share.
• Following the exercise, Eydelman sold 1,397 shares at a weighted average price of $66.594, with prices ranging from $66.185 to $67.13.
• Additionally, Eydelman sold 270 shares at a weighted average price of $67.416, with prices ranging from $67.37 to $68.10.
• After these transactions, Eydelman directly owns 30,597 shares of Vaxcyte common stock and holds options for 188,332 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions by an officer under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned and not based on immediate insider knowledge.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates